We are live on ! Find out more
SAM

Senzar Asset Management Portfolio holdings

AUM $34.7M
1-Year Est. Return 0.56%
This Fund
S&P 500
This Quarter Est. Return
+2.37%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$406M
AUM Growth
+$11.5M
Cap. Flow
+$7.41M
Cap. Flow %
1.83%
Top 10 Hldgs %
76.7%
Holding
35
New
7
Increased
8
Reduced
8
Closed
12

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$36.3M
2
LLY icon
Eli Lilly
LLY
+$33.9M
3
VTRS icon
Viatris
VTRS
+$26.5M
4
AERI
Aerie Pharmaceuticals
AERI
+$18.2M
5
CVS icon
CVS Health
CVS
+$17.9M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$69.6M
2
BIVV
Bioverativ Inc. Common Stock
BIVV
+$18.7M
3
MDXG icon
MiMedx Group
MDXG
+$16.1M
4
GMED icon
Globus Medical
GMED
+$13.2M
5
MYGN icon
Myriad Genetics
MYGN
+$9.96M

Sector Composition

Rank Sector Weight
1 Healthcare 90.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HALO icon
1
Halozyme
HALO
$9.14B
$52.4M 12.9%
4,087,264
+597,400
+17% +$7.98M
ESRX
2
DELISTED
Express Scripts Holding Company
ESRX
$40.9M 10.08%
641,301
+118,000
+23% +$7.41M
VTRS icon
3
Viatris
VTRS
$20.5B
$35.2M 8.67%
907,100
+690,400
+319% +$26.5M
NBIX icon
4
Neurocrine Biosciences
NBIX
$18B
$34.5M 8.49%
+749,200
New +$36.3M
LLY icon
5
Eli Lilly
LLY
$1.05T
$34.2M 8.41%
+415,200
New +$33.9M
ELV icon
6
Elevance Health
ELV
$82.9B
$27.2M 6.69%
144,350
-26,100
-15% -$4.69M
GILD icon
7
Gilead Sciences
GILD
$165B
$26.5M 6.51%
373,800
+53,200
+17% +$3.54M
ABT icon
8
Abbott
ABT
$174B
$21.9M 5.39%
450,700
+63,900
+17% +$2.89M
AERI
9
DELISTED
Aerie Pharmaceuticals
AERI
$20.6M 5.06%
+391,400
New +$18.2M
CVS icon
10
CVS Health
CVS
$137B
$18.2M 4.49%
+226,600
New +$17.9M
DVA icon
11
DaVita
DVA
$15B
$16.8M 4.13%
+258,800
New +$17.1M
FWP
12
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$13.3M 3.27%
93,214
+25,743
+38% +$3.58M
NDRM
13
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$10.7M 2.63%
357,400
+33,700
+10% +$873K
TGTX icon
14
TG Therapeutics
TGTX
$8.26B
$9.74M 2.4%
969,300
-170,600
-15% -$1.91M
LPNT
15
DELISTED
LifePoint Health, Inc.
LPNT
$8.98M 2.21%
133,700
-9,700
-7% -$613K
ALDR
16
DELISTED
Alder Biopharmaceuticals
ALDR
$6.39M 1.57%
557,770
+342,700
+159% +$6.34M
CORI
17
DELISTED
Corium International, Inc.
CORI
$6M 1.48%
803,766
-704,500
-47% -$4.19M
CNCE
18
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$5.75M 1.42%
412,145
-4,700
-1% -$69.3K
ACHN
19
DELISTED
Achillion Pharmaceuticals
ACHN
$4.97M 1.22%
+1,082,100
New +$4.35M
TVTX icon
20
Travere Therapeutics
TVTX
$5.26B
$4.78M 1.18%
246,289
-183,900
-43% -$3.34M
PTGX icon
21
Protagonist Therapeutics
PTGX
$8.64B
$3.09M 0.76%
+273,500
New +$2.92M
FOMX
22
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$2.64M 0.65%
569,197
-5,600
-1% -$25K
RCKT icon
23
Rocket Pharmaceuticals
RCKT
$375M
$1.6M 0.39%
210,931
-2,075
-1% -$15.5K
GMED icon
24
Globus Medical
GMED
$10.3B
– –
-447,100
Closed -$13.2M
MDXG icon
25
MiMedx Group
MDXG
$643M
– –
-1,692,850
Closed -$16.1M
1
2

Similar funds

BCP
Blum Capital Partners San Francisco, California $34.1M AUM 1.14% 1-Year Est. Return
PRHC
P.R. Herzig & Co Roslyn Heights, New York $45.9M AUM 15.88% 1-Year Est. Return
NAM
Needelman Asset Management Ladera Ranch, California $46M AUM 8.27% 1-Year Est. Return
GG
Gores Group Beverly Hills, California $22.3M AUM 4.58% 1-Year Est. Return
SM
SLS Management New York $17.2M AUM 14.82% 1-Year Est. Return
BC
Breogan Capital New York $56.4M AUM
SCPM
Social Capital PEP Management Palo Alto, California $56.5M AUM
FAM
Fortaleza Asset Management Chicago, Illinois $12.3M AUM 48.33% 1-Year Est. Return

Senzar Asset Management's Q2 2017 Portfolio in Review

As of Q2 2017, Senzar Asset Management held 35 positions worth $406M, up 2.9% from $395M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Senzar Asset Management's Q2 2017 filing shows 7 new, 8 increased, 8 reduced and 12 closed positions. Its largest new stake was Neurocrine Biosciences: 749,200 shares worth $34.5M. The largest sale was Sanofi, an estimated $69.6M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 94% a quarter earlier.

  • Senzar Asset Management's largest Q2 2017 buy was Neurocrine Biosciences: 749,200 shares worth $34.5M.
  • Senzar Asset Management added most to Viatris in Q2 2017, an estimated $26.5M increase.
  • Senzar Asset Management's biggest Q2 2017 reduction was Elevance Health, cutting an estimated $4.69M.
  • Senzar Asset Management fully exited Sanofi in Q2 2017, selling an estimated $69.6M.
  • Senzar Asset Management's ten largest holdings make up 77% of its $406M portfolio in Q2 2017.
  • Senzar Asset Management opened 7 new positions and closed 12 in Q2 2017.
  • Senzar Asset Management's portfolio value rose 2.9% quarter-over-quarter to $406M.

Based on Senzar Asset Management's 13F filing for Q2 2017, filed 11 Aug 2017.